While many tumor biology-centered approaches have been tried and failed, some mechanisms for treating within the realm of advanced cancer downstream systemic biology have proven successful in reducing the morbidity burden, and new trials are revealing potential pharmacological agents that may increase survival, such as those targeting the cytokine GDF-15. This evidence concerns the gene GDF15 and cancer.